A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.

被引：2
|
作者：
Krishnan, Amrita Y.
Patel, Krina K.
Hari, Parameswaran
Jagannath, Sundar
Niesvizky, Ruben
Silbermann, Rebecca Wang
Berg, Deborah T.
Li, Qing
Allikmets, Kristina
Stockerl-Goldstein, Keith
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[4] Mt Sinai Med Ctr, New York, NY 10029 USA
[5] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] Takeda Pharmaceut Int, Cambridge, MA USA
[8] Takeda Pharmaceut, Cambridge, MA USA
[9] Washington Univ, St Louis, MO 63110 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8539
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
    Krishnan, Amrita Y.
    Patel, Krina K.
    Hari, Parameswaran
    Jagannath, Sundar
    Niesvizky, Ruben
    Silbermann, Rebecca W.
    Berg, Deborah
    Lin, Jianchang
    Fedyk, Eric Robert
    Palumbo, Antonio
    Stockerl-Goldstein, Keith E.
    BLOOD, 2019, 134
  • [2] The Anti-CD38 Monoclonal Antibody TAK-079 Depletes Antibody Secreting Cells from Normal and SLE Patients
    Wang, Xiaoqian
    Dahl, Martin
    Nguyen, Doan
    Jenks, Scott
    Cashman, Kevin
    Lee, F. Eun-Hyung
    McLean, Lachy
    Sanz, Ignacio
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) - Final Primary Analysis
    不详
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S295 - S296
  • [4] HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) - Final Primary Analysis
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Harmenberg, Johan
    Byrne, Catriona
    Thuresson, Sara
    Obermueller, Jakob
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S295 - S295
  • [5] A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).
    Raab, Marc S.
    Goldschmidt, Hartmut
    Agis, Hermine
    Blau, Igor
    Einsele, Hermann
    Engelhardt, Monika Martha
    Ferstl, Barbara
    Gramatzki, Martin
    Roellig, Christoph
    Weisel, Katja
    Kloepfer, Pia
    Weinelt, Dominika
    Haertle, Stefan
    Peschel, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial
    Roepcke, Stefan
    Plock, Nele
    Yuan, Josh
    Fedyk, Eric R.
    Lahu, Gezim
    Zhao, Lin
    Smithson, Glennda
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2018, 6 (03):
  • [7] Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
    Shah, Bhavesh
    Gray, Joy
    Abraham, Ivo
    Chang, Melody
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 170 - 182
  • [8] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richter, Joshua
    Vij, Ravi
    Cole, Craig
    Zonder, Jeffrey
    Kaufman, Jonathan L.
    Bensinger, William
    Dimopoulos, Meletios
    Lendvai, Nikoletta
    Hari, Parameswaran
    Ocio, Enrique M.
    Gasparetto, Cristina
    Kumar, Shaji
    Oprea, Corina
    Chiron, Marielle
    Brillac, Claire
    Charpentier, Eric
    San-Miguel, Jesus
    Martin, Thomas
    LEUKEMIA, 2020, 34 (12) : 3298 - 3309
  • [9] A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
    Joseph Mikhael
    Joshua Richter
    Ravi Vij
    Craig Cole
    Jeffrey Zonder
    Jonathan L. Kaufman
    William Bensinger
    Meletios Dimopoulos
    Nikoletta Lendvai
    Parameswaran Hari
    Enrique M. Ocio
    Cristina Gasparetto
    Shaji Kumar
    Corina Oprea
    Marielle Chiron
    Claire Brillac
    Eric Charpentier
    Jesús San-Miguel
    Thomas Martin
    Leukemia, 2020, 34 : 3298 - 3309
  • [10] HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody - Primary and Subgroup Analysis
    Richardson, Paul
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Byrne, Catriona
    Mateos, Maria-Victoria
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S27 - S28
12345